At this time actuarial survival for the entire series is 43% at one year, 40% at two years and a projected 26% at three years. In those patients undergoing transplantation since 1970, there has been an over-all 50% one year survival rate.2 Thirty-two patients (54.4%) in this series survived longer than three months after transplantation, for a current total survival of 50.8 patient years. There are at this time 23 surviving recipients, of whom 20 lived for periods of three to 49 months following operation.
A CUTE GRAFT REJECTION and the consequences of its treatment continue to be the major factors limiting survival of the patient with a cardiac allograft. The recognition and treatment of acute rejection in the early postoperative period has been previously described in detail.' In contrast, little information has been presented on the incidence and significance of late acute graft rejection in the long-term cardiac transplant survivor. Thirty-two patients in the Stanford cardiac transplantation series have lived more than three months after operation.2 Our experience with the
Immunosuppression
Endomyocardial biopsy diagnosis and treatment of acute rejection episodes in these long-term survivors form the basis for this report.
Patients and Methods
Fifty-nine patients have undergone cardiac transplantation for end-stage cardiac disease at the Stanford University Medical Center between January, 1968, and June, 1973. Our experience with patient selection, tissue typing, operative technique and early postoperative care has been detailed in previous publications.3 6 At this time actuarial survival for the entire series is 43% at one year, 40% at two years and a projected 26% at three years. In those patients undergoing transplantation since 1970, there has been an over-all 50% one year survival rate.2 Thirty-two patients (54.4%) in this series survived longer than three months after transplantation, for a current total survival of 50.8 patient years. There are at this time 23 surviving recipients, of whom 20 lived for periods of three to 49 months following operation.
Immunosuppression
Cardiac transplant patients are maintained indefinitely on long-term immunosuppressive therapy (table 1) . At three months post-transplantation the usual daily prednisone dose is 0.75 mg/kg, which is reduced at six Endomyocardial biopsy has proved to be a useful technique for identification of the histologic changes associated with acute rejection. There has been good correlation between the clinical assessment of allograft function during rejection and the histologic changes seen on endomyocardial biopsy. Biopsies obtained on patients who are clinically stable revealed normal-appearing myocardium. The severity of the rejection process can be accurately graded from the biopsy and modifications in the immunosuppressive therapy. It is hoped that repeat biopsy after treatment, to confirm the complete reversal of the histologic changes, will assure appropriate treatment and therefore prevent permanent damage to myocytes and resultant fibrosis. In those patients with a poor clinical response to treatment of rejection, a repeat endomyocardial biopsy is used to differentiate continued rejection from residual myocyte damage.
Treatment of acute rejection in the long-term survivor is usually successful, particularly if the findings of graft dysfunction are mild (table 3) . Most patients continue near normal activities during treatment of the rejection episode. Treatment of these mild episodes has not been associated with any direct morbidity. The occurrence of repeated episodes of late acute rejection increases the risk of permanent graft dysfunction or death due to the complications of treatment. This experience is similar to the early period following surgery when the frequent occurrence of acute rejection markedly decreases the risk of long-term survival. ' The precise mechanisms responsible for the continued occurrence of acute rejection in the longterm survivor remain unclear. Four episodes of late acute rejection occurred within two weeks after tapering of maintenance prednisone, suggesting inadequate immunosuppression as a factor in these instances. Immunologic mechanisms are still operative in the late acute rejection episode, as lymphocytes and plasma cells staining with MethylGreen-Pyronin are frequently present in biopsy specimens. These cells may play a role in producing myocyte and vascular damage.
The relationship between the occurrence of acute rejection in the long-term survivor and the development of graft coronary artery atherosclerosis in the transplanted heart merits discussion. Damage to the coronary arterial intima has been histologically documented during acute rejection episodes and may be a factor predisposing to the future development of graft atherosclerosis.12 The frequency and severity of acute rejection may be a factor in the development of these changes, but further analyses of all possible risk factors is necessary before a final conclusion can be drawn. It should be stressed that there has been an apparently marked decrease in the appearance of these changes in the more recent long-term survivors in this series. "1 The fact that acute rejection occurs less frequently, and is less severe clinically and histologically, suggests that a state of limited tolerance does develop in the majority of long-term survivors. This is similar to the experience with renal allografts and supports our hypothesis that long-term survival of the cardiac allograft can be expected in those patients surviving the critical first few months after operation.
